Skip to main content
OpenTrials

Clinical trial condition

Harboring EGFR Sensitive Mutations NSCLC

Explore clinical trials studying Harboring EGFR Sensitive Mutations NSCLC. Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

Harboring EGFR Sensitive Mutations NSCLC trial results

Recruiting

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

NCT06735391

Conditions
Harboring EGFR Sensitive Mutations NSCLC, Locally Advanced or Metastatic Non-squamous NSCLC, Previously Untreated Systematically NSCLC
Locations
  • Sun Yat sen University Cancer Prevention and Treatment Center Guangzhou, China
View Trial Details

Related conditions